Compare Monster Beverage Corp (MNST) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Organon & Co. Common Stock — how do they compare? Monster Beverage Corp trades at $44.52 (market cap $84.85B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Monster Beverage Corp is far larger — about 23.4× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Monster Beverage Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and Organon & Co. Common Stock for 0 Days on average.
| MNST | OGN | |
|---|---|---|
Market Cap | $84.85B | $3.62B |
Volume | 7,847,331 | 2,892,999 |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $13.81 |
52-Week Low | $33.16 | $5.70 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $83.14B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $44.22, up 1.05% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.30, and maintains robust fundamentals including 55.55% gross margin and 23.08% net margin. Recent news highlights international growth, a debt-free balance sheet, and a 1:2 stock split effective August 2026.
Outlook remains positive with analyst consensus target of $98.22 implying significant upside, supported by international expansion and high profitability. Key risks include valuation multiples above industry averages and regulatory challenges in markets like India. The stock's growth trajectory is solid, but investors should weigh rich valuations against execution risks.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
